Technology
Health
Biotechnology

INmune Bio

$5.35
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.57 (-9.62%) Today
+$0.03 (0.50%) As of 4:00 PM EDT after-hours

Why Robinhood?

You can buy or sell INmune Bio and other stocks, options, ETFs, and crypto commission-free!

About INMB

INmune Bio Inc. Common stock, also called INmune Bio, is a clinical stage biotechnology company, which develops immunotherapies that reprogram a patient's innate immune system to allow the immune system to fight cancer. Read More Its products include INKMUNE and INB03. The company was founded by Mark Lowdell in September 2015 and is headquartered in La Jolla, CA.

Employees
3
Headquarters
La Jolla, California
Founded
2015
Market Cap
57.29M
Price-Earnings Ratio
Dividend Yield
Average Volume
59.58K
High Today
$5.72
Low Today
$5.06
Open Price
$5.72
Volume
23.34K
52 Week High
$11.50
52 Week Low
$5.06

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2019 IPO
US
North America

INMB Earnings

-$0.20
-$0.20
-$0.19
-$0.19
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 20, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.